Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Lambda-1a for SARS-CoV-2
NCT04344600Phase 2Terminated
- Sponsor
- Johns Hopkins University
- Start
- Jun 2020
- Primary completion
- Sep 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing Peginterferon lambda alfa-1a with Placebo (2 arms). Primary endpoint: Number of Participants With no Evidence of SARS-CoV-2 Infection at 28 days. Started Jun 2020; status: terminated.
02
Drugs
peginterferon lambda-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04344600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344600.